

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



KELUN-BIOTECH
科伦博泰

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

四川科倫博泰生物醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6990)

INSIDE INFORMATION
COMPLETION OF THE H SHARE FULL CIRCULATION
BY THE COMPANY

This announcement is made by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the “**Company**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

References are made to the announcements of the Company dated October 23, 2023, November 3, 2023, November 14, 2023 and November 17, 2023 (the “**Announcements**”) in relation to the proposed implementation of the H Share Full Circulation of certain domestic shares and unlisted foreign shares of the Company. Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the Announcements.

COMPLETION OF THE H SHARE FULL CIRCULATION

The Board is pleased to announce that the conversion of an aggregate of 62,567,234 domestic shares and unlisted foreign shares of the Company was completed on November 24, 2023 and the listing of the Converted H Shares on the Stock Exchange will commence at 9:00 a.m. on November 27, 2023.

SHARE CAPITAL UPON COMPLETION OF THE CONVERSION AND LISTING

The share capital structure of the Company immediately before and upon completion of the Conversion and Listing is as follows:

Description of shares	Immediately before completion of the Conversion and Listing		Upon completion of the Conversion and Listing	
	<i>Number of shares</i>	<i>Approximate percentage of the Company's total share capital</i>	<i>Number of shares</i>	<i>Approximate percentage of the Company's total share capital</i>
Domestic Shares	149,589,850	68.24%	87,157,052	39.76%
Unlisted Foreign Shares	5,548,478	2.53%	5,414,042	2.47%
H Shares	64,057,171	29.22%	126,624,405	57.77%
Total	219,195,499	100.00%	219,195,499	100.00%

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
LIU Gexin
Chairman of the Board and Non-executive Director

Hong Kong, November 24, 2023

As at the date of this announcement, the Board comprises Mr. LIU Gexin as the chairman of the Board and non-executive Director, Dr. GE Junyou and Dr. WANG Jingyi as executive Directors, Mr. LIU Sichuan, Mr. FENG Hao, Mr. ZENG Xuebo and Mr. LI Dongfang as non-executive Directors, and Dr. ZHENG Qiang, Dr. TU Wenwei, Dr. JIN Jinping and Dr. LI Yuedong as independent non-executive Directors.